Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-024-02168-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Tomomi Kogiso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan…. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Carcinoma, Hepatocellular, Fontan Procedure, Cholagogues and Choleretics. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Global Health and Medicine.
Abstract (Originalsprache)
Background
Fontan-associated liver disease (FALD) is a type of progressive liver fibrosis that occurs following Fontan surgery and can be complicated by hepatocellular carcinoma (HCC). Established treatments for FALD are lacking. Therefore, we investigated the efficacy of ursodeoxycholic acid (UDCA) in patients with FALD.
Methods
This single-center retrospective study was conducted from 2003 to 2024 and involved 220 patients (103 men, 46.8%) who had been diagnosed with FALD. UDCA was administered to 113 patients presenting with liver or biliary enzyme abnormalities. We evaluated the patients’ liver enzyme levels 3, 6, and 12 months after treatment. HCC developed in 10.5% and the mortality rate was 4.5%. Survival and cumulative incidence of HCC were compared between patients with and without UDCA treatment using Kaplan–Meier curves and propensity-matched analysis ( n = 68 per group).
Results
UDCA treatment significantly reduced the aspartate aminotransferase (AST), alanine transaminase (ALT), and gamma-glutamyl transferase (GGT) levels at 3 months. The mean pretreatment AST/ALT/GGT levels were 26/22/323 U/L, respectively, and decreased to 19/15/102 U/L at 3 months, 18/12/88 U/L at 6 months, and 16/19/64 U/L at 12 months. However, the total bilirubin level and platelet count did not show significant differences. The survival rate was higher and the HCC rate was lower in patients with than without UDCA treatment. The 5-year incidence rate of HCC was 5.6% in the UDCA group and 24.2% in the untreated group.
Conclusions
UDCA treatment significantly reduced liver enzyme levels, including GGT, and mitigated the progression of HCC. UDCA may be beneficial for patients with FALD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. kogiso.tomomi@twmu.ac.jp.
- Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
- Pediatric cardiology and adult congenital cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
- Japan Community Health care Organization Tokyo Joto Hospital, 9-13-1 Kameido, Koto-ku, Tokyo, 136-0071, Japan.
ORCID-Profile: Tomomi Kogiso
Förderung
- National Center for Global Health and Medicine
Zitieren
APA
Kogiso, T., Ogasawara, Y., Taniai, M., Shimada, E., Inai, K., Tokushige, K., & Nakai, Y. (2025). Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02168-x
Vancouver
Kogiso T, Ogasawara Y, Taniai M, Shimada E, Inai K, Tokushige K, et al. Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02168-x
BibTeX
@article{Kogiso2025,
author = {Kogiso, Tomomi and Ogasawara, Yuri and Taniai, Makiko and Shimada, Eriko and Inai, Kei and Tokushige, Katsutoshi and Nakai, Yousuke},
title = {Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-024-02168-x}
}
EUVIMED